{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:43:35Z","timestamp":1791078215731,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1097\/01.fjc.0000246853.15926.d4","type":"journal-article","created":{"date-parts":[[2006,11,13]],"date-time":"2006-11-13T10:01:08Z","timestamp":1163412068000},"page":"199-206","source":"Crossref","is-referenced-by-count":34,"title":["In Vitro Preclinical Cardiac Assessment of Tolterodine and Terodiline: Multiple Factors Predict the Clinical Experience"],"prefix":"10.1097","volume":"48","author":[{"given":"Ruth L","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T","family":"Limberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D","family":"Palmatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon D","family":"Cowart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan F","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A","family":"Gintant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210208","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00002018-200124090-00005","article-title":"Safety profile of tolterodine as used in general practice in England.","volume":"24","author":"Layton","year":"2001","journal-title":"Drug Safety"},{"key":"R2-2-20210208","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","article-title":"Tolterodine: a safe and effective treatment for older patients with overactive bladder.","volume":"49","author":"Malone-Lee","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"R3-2-20210208","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/14656566.6.4.653","article-title":"Tolterodine for the treatment of overactive bladder: a review.","volume":"6","author":"Rovner","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"R4-2-20210208","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2165\/00002018-200427130-00005","article-title":"Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.","volume":"27","author":"Garely","year":"2004","journal-title":"Drug Safety"},{"key":"R5-2-20210208","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1034\/j.1600-0773.2002.900506.x","article-title":"Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists.","volume":"90","author":"Nilverbrant","year":"2002","journal-title":"Pharmacol Toxicol"},{"key":"R6-2-20210208","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y","article-title":"Serum protein binding of tolterodine and its major metabolites in humans and several animal species.","volume":"20","author":"Pahlman","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"R7-2-20210208","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2165\/00003495-199040050-00008","article-title":"Terodiline. a review of is pharmacological properties, and therapeutic use in the treatment urinary incontinence.","volume":"40","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"R8-2-20210208","first-page":"13","article-title":"Clinical pharmacology of terodiline.","volume":"87","author":"Andersson","year":"1984","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"R9-2-20210208","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0773.1995.tb00125.x","article-title":"Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites.","volume":"76","author":"Hallen","year":"1995","journal-title":"Pharmacol Toxicol"},{"key":"R10-2-20210208","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00540958","article-title":"Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients.","volume":"34","author":"Hallen","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"R11-2-20210208","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/BF00558074","article-title":"Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence.","volume":"36","author":"Hallen","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-2-20210208","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0140-6736(91)90481-4","article-title":"Torsades de pointes ventricular tachycardia and terodiline.","volume":"338","author":"Connolly","year":"1991","journal-title":"Lancet"},{"key":"R13-2-20210208","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/bmj.302.6790.1469-c","article-title":"Torsades de pointes complicating treatment with terodiline.","volume":"302","author":"McLeod","year":"1991","journal-title":"BMJ"},{"key":"R14-2-20210208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF00265918","article-title":"Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval.","volume":"42","author":"Stewart","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"R15-2-20210208","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/hrt.74.1.53","article-title":"Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.","volume":"74","author":"Thomas","year":"1995","journal-title":"Br Heart J"},{"key":"R16-2-20210208","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.bjp.0702173","article-title":"Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline.","volume":"125","author":"Jones","year":"1998","journal-title":"Br J Pharmacol"},{"key":"R17-2-20210208","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0703595","article-title":"Differences in the effects of urinary incontinence agents S-oxbutynin and terodiline on cardiac K+ currents and action potentials.","volume":"131","author":"Jones","year":"2000","journal-title":"Br J Pharmacol"},{"key":"R18-2-20210208","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0022-3565(24)35049-9","article-title":"Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.","volume":"290","author":"Shuba","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-2-20210208","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.103.062182","article-title":"Cardiac ion channel effects of tolterodine.","volume":"308","author":"Kang","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R21-2-20210208","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of hERG channels stably expressed in HEK293 cells studied at physiological temperatures.","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophys J"},{"key":"R22-2-20210208","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00005344-200105000-00012","article-title":"The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.","volume":"37","author":"Gintant","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"R23-2-20210208","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yjmcc.2003.10.017","article-title":"Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel.","volume":"36","author":"Su","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"R25-2-20210208","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc Res"},{"key":"R26-2-20210208","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bjp.0701575","article-title":"Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action.","volume":"123","author":"Busch","year":"1998","journal-title":"Br J Pharmacol"},{"key":"R27-2-20210208","first-page":"1324","article-title":"Use-dependent agonist effect of azimilide on the HERG channel.","volume":"291","author":"Jiang","year":"1999","journal-title":"J Pharmacol Exp Toxicol"},{"key":"R28-2-20210208","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s002100000392","article-title":"Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel.","volume":"363","author":"Mergenthaler","year":"2001","journal-title":"Naunyn Schmiederbergs Arch Pharmacol"},{"key":"R29-2-20210208","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bjp.0704784","article-title":"Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.","volume":"136","author":"Paul","year":"2002","journal-title":"Br J Pharmacol"},{"key":"R30-2-20210208","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/oxfordjournals.eurheartj.a061881","article-title":"Malignant ventricular tachyarrhythmias in association with propafenone treatment.","volume":"6","author":"Buss","year":"1985","journal-title":"Eur Heart J"},{"key":"R31-2-20210208","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1540-8159.1991.tb02729.x","article-title":"Propafenone-induced torsade de pointes: cross-reactivity with quinidine.","volume":"14","author":"Hii","year":"1991","journal-title":"Pacing Clin Electrophysiol"},{"key":"R32-2-20210208","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/00912700222011436","article-title":"Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.","volume":"42","author":"Pritchett","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R33-2-20210208","first-page":"637","article-title":"Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.","volume":"276","author":"Bril","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R34-2-20210208","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005344-200403000-00007","article-title":"The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block.","volume":"43","author":"Martin","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"R35-2-20210208","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.RES.84.9.989","article-title":"Mechanisms of block and identification of the verapamil binding domain to hERG potassium channels.","volume":"84","author":"Zhang","year":"1999","journal-title":"Circ Res"},{"key":"R36-2-20210208","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1540-8167.1995.tb00418.x","article-title":"In vivo and in vitro electrophysiologic effects of terodiline on dog myocardium.","volume":"6","author":"Pressler","year":"1995","journal-title":"J Cardiovasc Electrophysiol"},{"key":"R37-2-20210208","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/01.CIR.103.15.2004","article-title":"Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.","volume":"103","author":"Hondeghem","year":"2001","journal-title":"Circulation"},{"key":"R38-2-20210208","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00005344-200301000-00003","article-title":"Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability.","volume":"41","author":"Hondeghem","year":"2003","journal-title":"J Cardiovasc Pharm"},{"key":"R39-2-20210208","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.hrthm.2005.03.023","article-title":"Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.","volume":"2","author":"Shah","year":"2005","journal-title":"Heart Rhythm"},{"key":"R40-2-20210208","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1540-8159.2005.09404.x","article-title":"Effects of epinephrine on right ventricular monophasic action potentials in the LQT1 versus LQT2 form of long QT syndrome: preferential enhancement of triangulation in LQT1.","volume":"28","author":"Viitasalo","year":"2005","journal-title":"Pacing Clin Electrophysiol"},{"key":"R41-2-20210208","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.bjp.0706070","article-title":"Prediction of the risk of torsade de pointes using the model of isolated canine Purkinje fibres.","volume":"144","author":"Champeroux","year":"2005","journal-title":"Br J Pharmacol"},{"key":"R42-2-20210208","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(02)02246-X","article-title":"Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations.","volume":"452","author":"Lu","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R43-2-20210208","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/jpet.102.035220","article-title":"The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.","volume":"302","author":"Fossa","year":"2002","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00005344-200611000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T22:52:38Z","timestamp":1736635958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005344-200611000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.fjc.0000246853.15926.d4","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}